WO2020171784A1 - Produit laitier d'origine humaine et/ou animale, approprié pour être utilisé comme produits pharmaceutiques, cosméceutiques et complément alimentaire pour éliminer et prévenir divers troubles - Google Patents

Produit laitier d'origine humaine et/ou animale, approprié pour être utilisé comme produits pharmaceutiques, cosméceutiques et complément alimentaire pour éliminer et prévenir divers troubles Download PDF

Info

Publication number
WO2020171784A1
WO2020171784A1 PCT/TR2019/050299 TR2019050299W WO2020171784A1 WO 2020171784 A1 WO2020171784 A1 WO 2020171784A1 TR 2019050299 W TR2019050299 W TR 2019050299W WO 2020171784 A1 WO2020171784 A1 WO 2020171784A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
milk
semen
vapor
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2019/050299
Other languages
English (en)
Inventor
Osman ONER
Mustafa Menguc ONER
Egemen ONER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2020171784A1 publication Critical patent/WO2020171784A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206—Colostrum; Human milk
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C1/00—Concentration, evaporation or drying
    • A23C1/12—Concentration by evaporation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986—Milk; Derivatives thereof, e.g. butter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • a Dairy Product of Human and/or Animal Origin Suitable for Use as Pharmaceuticals, Cosmeceuticals and Food Supplement for Eliminating and
  • the present invention related to a dairy product of human and/or animal origin suitable for use as pharmaceutical, cosmeceuticals and food supplement for eliminating and preventing various disorders.
  • Milk is a white liquid food with a high nutritional value, which is used by the mammals to feed their babies.
  • milk powder and whey are the main dairy products widely used in the food industry.
  • the chorion which occupies a wide area on the placenta where it connects with the umbilical cord and where the bloods of mother and fetus do not mix with each other and the fluid surrounding the fetus is called the amnion fluid.
  • the fetus in the mother's womb exchanges substances not only from the umbilical cord but also from the amniotic fluid. In this way, food and preservatives such as IgG and water are taken.
  • Milk powder in the prior art is a durable and highly nutritional dairy product and is obtained by evaporation of water in milk such that the remainder is in a powder form. Milk powder can be obtained in various ways. In all production methods of the milk powder in prior art, water in milk is evaporated and remaining material is used. Milk vapor is released into the atmosphere.
  • Whey used in the prior art is the residual liquid in cheese production, which is deposited at the bottom of the buckets after cheese is taken. In some countries it is consumed as a beverage. In food industry, it is pulverized and used as an additive in order to increase the protein value of the food. By heating the whey in order to evaporate some water content, it is converted into a sort of cream or entire water content is evaporated through various process steps in order to get a solid powder form. At the end, the solid part of whey is used.
  • MFGM-Milk Fat Globule Membrane which is used as an additive and food supplement in food which has been proven to be beneficial to newborn children and people, is obtained from the creamy material of whey. Evaporated water is released into the atmosphere.
  • a milk powder preparation method is mentioned in European Patent document No. EP1127494 available in prior art.
  • the process mentioned is based on following process steps which are composed of; preparing a standardized milk, feeding the prepared standardized milk to an evaporator with at least one stage to obtain the pre-concentrate, the pre-concentrate and re-evaporating the pre concentrate in the evaporator with at least one stage and drying it by spraying in order to obtain a concentrate with at least 50% solid content by weight.
  • the vapor obtained as the result of evaporation performed as part of the process steps mentioned in such patent documentation is released to the atmosphere.
  • the remaining concentrated product is then converted into milk powder.
  • a method for producing protein concentrate from acid whey and the use of such protein concentrate are mentioned in the European Patent Document with the number EP1611795 available in current art.
  • Said invention is related to a method for producing a protein concentrate from acid whey wherein the acid whey is subject to filtration, the permeability or retention capability of the membrane is selected based on the molar mass of ingredients of the acid whey, which is composed of the process steps concerning acid whey filtration through a nano filtration valve, filtering the acid whey by using at least one selective membrane for separating the protein parts or whey proteins, heat treating the ingredients retained during filtering and pulverization of heat treated particles or tiny pieces with an average particle size.
  • the ingredients which are retained during filtration are used. Evaporation of whey and use of vapor upon condensation are not in question.
  • CT Computer tomography
  • X-rays X-rays
  • people diagnosed with cancer receive chemotherapy.
  • the drugs used in chemotherapy give damage to the body, too.
  • cancerous cells emerge 7-8 times in a human or animal body throughout the life period and the body beats it (the cancer) for 6-7 times. This means that if the body is strong enough, it can cure the cancer by its own means.
  • advertising and information posters "early diagnosis saves lives, make check-up every year for sure" message is given.
  • this problem solving information is transmitted to all or some of the babies. Those who are not transmitted with this information, cannot pass it over to those that are derived from them. In this way, the generations of those, who have been transmitted with this information will multiply for years, centuries, millenniums and tens of thousands of years, while others, who were not transmitted, will be eliminated, and will get extinct. This is called natural selection.
  • boundary cells Every cell of humans and animals must be fed. Each cell takes the nutrients through its protective membrane, from the medium which surrounds and is in contact with such membrane.
  • the medium contains other neighboring cells, fluids present in the intercellular spaces and immune system cells that come back and forth for control occasionally.
  • boundary cells receive nutrients from the boundary medium.
  • the boundary medium is the blood for the inner layers of vessels, i.e. the substances and blood cells inside the blood.
  • boundary medium is everything that is inside the intestines.
  • boundary medium is the air and water as well as substances inside water while having a shower.
  • Boundary skin cells absorb the absorbable and transferable materials and foods, and then transfer them into interior, just like the intestinal cells absorb and transfer the absorbable and transferable substances.
  • Boundary skin cells absorb the absorbable and transferable materials and foods, and then transfer them into interior, just like the intestinal cells absorb and transfer the absorbable and transferable substances.
  • the internal organs like kidneys, liver, pancreas, for their outer layer cells, spaces surrounding them are the boundary media described above. And these organs absorb food or material from their boundary media, if those materials are absorbable and transferable and then transfer them into the interior of the organs.
  • the purpose of the present invention is to obtain a dairy product that can be used as food supplement, cosmeceuticals and pharmaceuticals.
  • Another purpose of the present invention is to create a product indicated for the prevention and treatment of fatigue, transient ischemic attack, cataract, cough attacks, fever, shortness of breath, heart disease, injury, cuts or bruises resulting from trauma, joint pain, hair loss, gum disease, eating disorders, bloody semen, insufficient volume of semen and ADHD (Attention Deficit Hyperactivity Disorder) mostly seen in children.
  • Another purpose of the present invention is to obtain a product that is good for joint pains and headaches.
  • Another purpose of the present invention is to obtain a product that keeps human beings fit and sound.
  • Another purpose of the present invention is to obtain a product that allows quick healing for wounds. Another purpose of the present invention is to obtain a product that prevents obesity.
  • Another purpose of the present invention is to obtain a product that can be used as a diagnostic material.
  • the product developed to realize the aforementioned objectives is a product which is obtained by boiling milk and/or whey by applying heat and vacuum or pressure, and then cooling down the vapor generated and condensing it.
  • Milk is a white, highly nutrient liquid produced in the breasts of the mammals, which is used for feeding their babies.
  • the invention is about the substance obtained by cooling the vapor of the milk boiled in a closed system and then converting it into liquid form.
  • the invention may also be used as vapor.
  • the product according to the invention can be obtained through different methods. 12.6% of cow's milk is dry substance. The dry substance ratio in milk varies for different animals. Apart from said dry substance, there are various useful components in milk. Components other than the dry substance in milk can be evaporated at different temperatures depending on certain pressure or vacuum values.
  • the invention is related to a product obtained by condensing the vapor generated when the milk is boiled as the result of such evaporation process. Its color, smell and taste are similar to water. In alternative embodiments, different colors, odors and flavors may be present since different kinds of milk may be used to obtain the invention.
  • One or more of the humans, cow, sheep, goat, buffalo, mare, camel, elephant, whale, cat, mouse, dog, hare, reindeer or donkey milk may be used in order to obtain the product of the invention.
  • the product obtained can be used by converting it into a cream form or a solid (ice) form.
  • it can be used as a pharmaceutical in tablet, capsule, coated pill, suspension, syrups, powder, granule, solution, ovule, lotion, gel, ampoule, vial, aerosols (inhaler) etc. forms.
  • the product subject to the invention which is available in such tablet, capsule, coated pill, granule forms, is used in doses between 1000 and 4000 mg/day.
  • the product subject to the invention which is available in such liquid, suspension, syrup, solution, ovule, lotion, gel, ampoule forms, is used in doses between 1 and 4 cc/day.
  • the invention is obtained through the following process steps;
  • the vapor obtained in third step is used directly.
  • the invention can be used as food supplement, cosmeceuticals and pharmaceuticals once it is obtained in liquid form.
  • the invention may be taken orally or used as an ointment and as injection. It can also be taken from the respiratory system and the digestive system.
  • the product subject to the invention is used by mixing with isosorbide dinitrate (ISDN) in certain proportions in an alternative embodiment.
  • the product subject to the invention contains 0.1% isosorbide dinitrate (ISDN) by weight. In another embodiment, it contains isosorbide dinitrate (ISDN) in the range of 0.01 to 0.2% by weight.
  • the ratio may vary in alternative embodiments. Thus, the effect of the invention is increased for some disorders.
  • the product subject to the present invention contains a preservative in another alternative embodiment.
  • the shelf life of the product subject to the invention is prolonged.
  • the product subject to the invention When the product subject to the invention is taken orally, it mixes into blood and carried to necessary points through the circulation system and/or lymphatic system.
  • the invention should be taken orally on an empty stomach and with plenty of water.
  • the invention referred When the invention referred is taken with plenty of water, it is neither tried to be digested by the digestive system nor is subject to any decomposition at intestines and liver.
  • the invention delivers a general well-being for human or animal when it is taken orally as 3-4 cc.
  • the areas with local problems get this benefit with delay. Therefore, it is more useful to perform local applications in addition to oral use and this type of use is recommended.
  • the invention may be used by mixing with water or some other substances.
  • water and other substances contained in the product may be taken away and then can be used as a concentrated active material.
  • the invention can be applied to any discomforted and/or desired part of the body. Since the invention is obtained in liquid form, it is sufficient to rub it by hand and then apply deeply into the skin after it is applied on to the desired area. Thus, the product subject to the invention will be absorbed by the surface it is applied and will contribute to the direct healing of that surface. Thus, the product subject to the invention will be absorbed by the upper skin cells on the applied surface and some portion of the same will be carried in to the deeper cells through the lymphatic and capillary vessels and other parts of the body through the systemic circulation. It will directly contribute to the healing of the applied surface and the area under the surface. In addition, it will also provide general benefit for the whole body.
  • the invention is absorbed from the scalp when applied to the head.
  • the product subject to the invention is delivered to the brain via capillaries in the head. Somehow, it passes through the blood-brain barrier and keeps it in fit condition by functioning as it does in other parts of the body.
  • skin By applying on the body surface (skin): it is applied on the head (eye, face, ear, etc.), arm, hand, body (chest, back, abdomen, etc.), leg, and genitals.
  • injection method it can be injected into any point of the body.
  • the product subject to the present invention can be applied with all generally systematic (parenteral, inhalation, enteral, transdermal) and / or local (on the skin, intrathecal, intrapleural, intraperitoneal, intracardiac, intraarticular, intraperitoneal, intravaginal, rectum or colon, conjunctival, intranasal, intraocular, buccal) drug application methods.
  • the invention can be used as a disease diagnostic product. If it is observed that there is no decrease or healing when the invention is applied on the discomforted areas and/head, it is understood that the problem is serious, and it must be treated with other methods.
  • the invention brings the sense of fullness when used orally and/or locally. It gives a sense of fullness in humans, especially when used with small amounts orally in small children. In this way, a possible obesity problem is prevented.
  • the invention reduces the risk for people to suffer from neurological diseases by keeping the brain and body fit when taken orally and/or by local administration. It provides benefit against ADHD (Attention Deficit Hyperactivity Disorder) mostly seen in children, which is known as impulsive disorder, which is manifested as excessive mobility in children.
  • ADHD Active Deficit Hyperactivity Disorder
  • the invention can be applied directly to the human body but can also be applied as a vapor by taking the milk vapor without being liquefied. Said method of application can be given to the environment in sauna-like rooms as steam or as spray. In addition, milk vapor is obtained by using a device similar to electronic cigarette and the vapor obtained can be inhaled through the respiratory system.
  • the invention is a product obtained from milk, which is a highly nutrient, white liquid food, used by the mammals to feed their babies and it is a liquid substance obtained by heating up the milk in a container and cooling down and condensing the vapor generated by boiling milk under pressure or vacuum for using it in preventing and treating fatigue, transient ischemic attack, cataract, cough attacks, fever, shortness of breath, heart disease, injury, cuts or bruises resulting from trauma, joint pains, hair loss, loose tooth as result of gum diseases, eating disorders causing continues sense of hunger, bloody semen, insufficient volume of semen and ADHD (Attention Deficit Hyperactivity Disorder ) mostly seen in children.
  • milk which is a highly nutrient, white liquid food, used by the mammals to feed their babies and it is a liquid substance obtained by heating up the milk in a container and cooling down and condensing the vapor generated by boiling milk under pressure or vacuum for using it in preventing and treating fatigue, transient ischemic attack, cataract, cough attacks, fever, shortness of breath, heart
  • it is a product obtained from whey and is a liquid substance obtained by heating up the whey in a container and cooling down and condensing the vapor generated by boiling milk under pressure or vacuum for using it in preventing and treating fatigue, transient ischemic attack, cataract, cough attacks, fever, shortness of breath, heart disease, cuts or bruises resulting from trauma, joint pains, hair loss, loose tooth as result of gum diseases, eating disorders causing continues sense of hunger, bloody semen, insufficient volume of semen and ADHD (Attention Deficit Hyperactivity Disorder) mostly seen in children.
  • ADHD Application Deficit Hyperactivity Disorder
  • physiological saline solution i.e. 0.9% NaCl is mixed with 99.1% of the product subject to invention.
  • Physiological saline solution is a substance kept ready in ampoules, which is made of pure water containing 0.9% of dissolved NaCl which ensures dissolution of any therapeutic medicine in powder form when it is administered to the human or animal body by injection.
  • Any injectable drug is in a vial and is surely supplied with an ampoule. The person, who performs the application to the patient, breaks the head of the ampoule and draws physiological saline solution into an injector.
  • the practitioner perforates the rubber cap on the vial containing the medication by using the injector needle and administers entire product drawn into the injector before, into the vial. He/she dissolves the medication in powder form by shaking. The solution is drawn back to the injector and administered to the patient.
  • the product obtained with the invention is absorbed from the skin on the applied area when it is applied to various parts of the body in various ways. In this way, it directly affects the applied area and its effect is observed in a short time.
  • the results obtained when the invention is applied to different parts of the body are described by following examples. If no explanation is given for the applications expressed in the examples, it should be continued to use 2-3 times a day for 4-7 days. In case of injection, it is continued to apply once a day for 6-7 days. It is mixed into the saline when administering into blood.
  • Fatigue is described as the reducing level of efficiency of a person in terms of physical and mental activities due to hard working or other reasons and not being capable of performing well. Fatigue is overcome by taking a break and resting for recovery. In other words, a certain time period needs to be passed after it.
  • the product subject to the invention shows effect immediately when applied to the tired organ, back or any part of the body and/or to the head in a way that moisturizes the applied area. Especially when applied to the head (face, neck, head, etc.), it is absorbed by the scalp, and the body feels the betterment quickly.
  • the product subject to this invention is absorbed by the scalp when applied to face. For example; there is extreme fatigue at eyes of a car driver.
  • the product subject to the invention is sprayed and massaged deeply onto the face 6-7 puffs, while the eyes are closed.
  • the eyes are closed.
  • the product obtained through the invention passes through the blood-brain barrier and shows effect immediately so that fatigue is eliminated without taking minutes.
  • Strain is referred to as the pain occurring somewhere in the body due to factors such as an impact, jamming, twisting etc.
  • the product subject to the invention When the product subject to the invention is applied to the strained surface, it acts quickly and accelerates the healing process.
  • transient ischemic attacks This is a kind of paralysis, a stroke. The symptoms are observed depending on the location of embolization in the brain.
  • the product subject to the invention is applied to the head of the person experiencing the attack (head, nape, neck, face), the severity of the attack decreases within 20-30 minutes and heals quickly.
  • the product obtained through the invention suppresses hunger and gives a feeling of satiety, when applied to the body or when taken orally. It is prevented that people who have eating disorder stimulating to eat continuously, catch the obesity disease.
  • cataract When the natural eye lens, which is located behind the pupil and allows seeing the objects, loses its transparency and becomes dull, this is called cataract.
  • product subject to the invention When the product subject to the invention is applied in the eye as a drop, it relieves the eye and accelerates the healing process. (The drop used is composed of 0.9% NaCl and 99.1% product obtained through the invention).
  • Fever is a reaction given by the body while fighting against microbes. Fever usually takes place and constitutes risk in infants.
  • Fever usually takes place and constitutes risk in infants.
  • the product subject to the invention was applied to the body, it was observed that said fever had rapidly decreased and recovered. Besides, reoccurrence of fever was delayed. (It was observed that fever had recovered in 3 days, thanks to applications performed in the morning and just before going to bed.)
  • the pain recurred after 2 years.
  • the product subject to the invention was applied on the point 3 times a day, for 1 week instead of 15% DCA, this time and the pain felt had gone.
  • the same problem reoccurred (third time) a year later.
  • the pain repeated after a while (4th time).
  • the product subject to the present invention was converted into physiological saline (0.5cc; 0.9% NaCl, 99.1% product of the invention) solution and applied on the area where there was swelling and aches when pressed. After the last application, pain was observed to decrease on the first day following the application. It was observed that the pain was nearly zero during the second subsequent day. (The product is applied 1-2 times a day).
  • the product subject the invention had reduced the problems of the patients suffering with shortness of breath, when applied in required amount. For example, a person, who can barely climb up a slightly sloped hill, can go up such hill easily when the product subject to the invention is applied on the body or head of such person.
  • Hair loss may occur due to seasonal changes, stress, iron deficiency and hormonal disorders.
  • the product subject to the invention reduces hair loss when applied to the hair.
  • the invention with ISDN is applied to the genitals at the beginning of early menopause and in early andropause.
  • vaginal application a piece of cotton pad is soaked with the invention with ISDN and placed on the cervix.
  • men the same is applied to the testicles at least once a day. This process is continued for several weeks. Men and women feel better immediately after the first use. The number of occasions on feeling hot (uncomfortably hot) decreases. Besides, vaginal smell, if any, is eliminated. Women and men feel fit and very well even at the beginning of the application. Furthermore, it was observed that the product was good for the burnout syndrome for men when it is applied immediately after every ejaculation and made him feel fitter.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un produit laitier d'origine humaine et/ou animale, qui est approprié pour être utilisé en tant que produits pharmaceutiques, cosméceutiques et complément alimentaire, pour éliminer et prévenir diverses maladies et divers troubles, caractérisé en ce que le produit présente des propriétés antitumorales et aphrodisiaques pour prévenir et traiter la fatigue, un accident ischémique transitoire, la cataracte, la toux, la fièvre, l'essoufflement, les maladies du cœur, les blessures, les coupures ou les ecchymoses résultant de traumatismes, les douleurs articulaires, la perte des cheveux, la maladie des gencives, des troubles de l'alimentation, le sperme sanglant, un volume insuffisant de sperme, le syndrome d'épuisement professionnel et un trouble déficitaire de l'attention avec hyperactivité (TDAH), principalement chez les enfants. Il s'agit du produit obtenu par refroidissement et liquéfaction de la vapeur formée par chauffage et ébullition du lait ou du lactosérum dans un récipient sous vide ou sous pression.
PCT/TR2019/050299 2019-03-28 2019-05-06 Produit laitier d'origine humaine et/ou animale, approprié pour être utilisé comme produits pharmaceutiques, cosméceutiques et complément alimentaire pour éliminer et prévenir divers troubles Ceased WO2020171784A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/04664A TR201904664A2 (tr) 2019-03-28 2019-03-28 Muhtelif Rahatsızlıkların Giderilmesi Ve Önlenmesinde Kullanılmak Üzere İlaç, Kozmetik Ve Gıda Takviyesi (Supplement) Olarak Kullanıma Uygun İnsan Ve/Veya Hayvan Kaynaklı Bir Süt Ürünü
TR2019/04664 2019-03-28

Publications (1)

Publication Number Publication Date
WO2020171784A1 true WO2020171784A1 (fr) 2020-08-27

Family

ID=67980058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050299 Ceased WO2020171784A1 (fr) 2019-03-28 2019-05-06 Produit laitier d'origine humaine et/ou animale, approprié pour être utilisé comme produits pharmaceutiques, cosméceutiques et complément alimentaire pour éliminer et prévenir divers troubles

Country Status (2)

Country Link
TR (1) TR201904664A2 (fr)
WO (1) WO2020171784A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2570212A (en) * 1946-09-09 1951-10-09 Mojonnier Bros Co Inc Milk evaporation process
EP0057726A1 (fr) * 1980-08-14 1982-08-18 Dmv Campina Bv Procédé et dispositif pour le traitement de petit-lait acide.
US20090220662A1 (en) * 2008-03-03 2009-09-03 Catherine Tachdjian Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2570212A (en) * 1946-09-09 1951-10-09 Mojonnier Bros Co Inc Milk evaporation process
EP0057726A1 (fr) * 1980-08-14 1982-08-18 Dmv Campina Bv Procédé et dispositif pour le traitement de petit-lait acide.
US20090220662A1 (en) * 2008-03-03 2009-09-03 Catherine Tachdjian Isosorbide derivatives and their use as flavor modifiers, tastants, and taste enhancers

Also Published As

Publication number Publication date
TR201904664A2 (tr) 2019-04-22

Similar Documents

Publication Publication Date Title
CN105497217A (zh) 一种用于润肠通便的中药保健制剂
STEINBERG Brucellosis as a cause of sacroiliac arthritis: a study of its relationship to rheumatoid spondylitis
TR201904664A2 (tr) Muhtelif Rahatsızlıkların Giderilmesi Ve Önlenmesinde Kullanılmak Üzere İlaç, Kozmetik Ve Gıda Takviyesi (Supplement) Olarak Kullanıma Uygun İnsan Ve/Veya Hayvan Kaynaklı Bir Süt Ürünü
US10959450B2 (en) Food composition for relieving symptoms of allergic and autoimmune diseases
CN104547989B (zh) 一种用于治疗脊椎病的藏药膏剂及其使用方法
Shreeve Alternative Dictionary Of Symptoms And Cures: A Comprehensive Guide to Diseases and Their Orthodox and Alternative Remedies
CN102319330A (zh) 一种治疗骨质增生的中药巴布膏及其制备方法
Hutchison The elements of medical treatment
Gland preservative or diluent.
Money Treatment of Disease in Children: Including the Outlines of Diagnosis and the Chief Pathological Differences Between Children and Adults
Moço Internship Report and Monography Entitled" Pharmaceutical Follow-Up of Women in the Postpartum Period"
Ganer et al. Chapter-2 Medico Legal Aspects of the Medicinal and Poisonous Plant Jayapala (Croton tiglium)
DAVIS OBSERVATIONS ON BREAST FEEDING FROM AN OBSTETRICIAN'S POINT OF VIEW.: WITH REPORT OF CASES.
Davis Obstetric and gynecologic nursing
Tuson The structure and functions of the female breast, as they relate to its health, derangement, and disease
CN111467453A (zh) 一种用于养心的中药组合物及其外用制剂和应用
Morse SELECTIONS AND ABSTRACTS.
WHITE Practical Notes.
World Health Organization Essential drugs for primary health care
Venkatrao General Principles Of Treatment Of Poisoning In Ayurveda And Modern Medicine: A Conceptual Study
REDDY Buddha’s discourses on Medicaments, Treatment and Nursing
Word Remarks, Gleanings, and Extracts
Hay THE ADVANTAGES IN THE TREATMENT OF SYPHILIS AT THE HOT SPRINGS OF ARKANSAS.
Bellinger AMERICAN INTELLIGENCE.
Paradis Henriette, la capuche: The Portrait of a Frontier Midwife

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19915849

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19915849

Country of ref document: EP

Kind code of ref document: A1